Korro Bio (KRRO) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

KRRO · Stock Price

USD 12.89-2.67 (-17.16%)

Market Cap: $170.2M

Historical price data

Overview

Korro Bio is a clinical-stage biotechnology company developing RNA editing therapies via its proprietary OPERA® platform, which co-opts the endogenous ADAR enzyme to make precise adenosine-to-inosine edits. The company has built a diversified pipeline of wholly-owned programs, with its lead candidate, KRRO-121, advancing towards the clinic for hyperammonemia. Korro's strategy leverages validated delivery technologies like GalNAc and LNPs to target high-need indications in the liver and CNS, supported by recent capital raises including an $85 million private placement in March 2026.

Metabolic & Liver DiseasesNeurology

Technology Platform

OPERA® platform co-opts endogenous ADAR enzyme with proprietary oligonucleotides to enable precise adenosine-to-inosine (A-to-I) RNA editing for therapeutic purposes.

Pipeline

1

1 drug in pipeline

Drug	Indication	Stage	Watch
KRRO-110	Alpha-1 Anti-trypsin Deficiency	Phase 1/2

Opportunities

Korro's RNA editing platform offers a potentially safer, tunable alternative to permanent DNA editing, applicable to both rare genetic corrections and large prevalent disease modulation.

The recent $85M financing provides a multi-year runway to generate critical clinical proof-of-concept for its lead hyperammonemia program, a significant near-term catalyst.

Risk Factors

The company faces substantial platform risk as RNA editing is an unproven clinical modality with no approved therapies, and the regulatory path is undefined.

Intense competition from other editing technologies and established oligonucleotide modalities, coupled with the high cash burn of clinical development, presents significant challenges.

Competitive Landscape

Korro competes directly with other ADAR-based RNA editing firms (Wave, ProQR, ShapeTx) and indirectly with DNA editing (CRISPR) and antisense/siRNA companies. Its differentiation hinges on demonstrating superior specificity, delivery, and a favorable tolerability profile for its transient CHORD oligonucleotides in the clinic.

More companies in RNA Therapeutics (non-mRNA) →More companies in United States →